D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$354M |
| 2 |
Wells Fargo
WFC
|
+$274M |
| 3 |
IBM
IBM
|
+$266M |
| 4 |
Qualcomm
QCOM
|
+$257M |
| 5 |
Mondelez International
MDLZ
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$356M |
| 2 |
PayPal
PYPL
|
+$290M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$261M |
| 4 |
NVIDIA
NVDA
|
+$248M |
| 5 |
AABA
Altaba Inc
AABA
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.61% |
| 2 | Healthcare | 10.26% |
| 3 | Consumer Discretionary | 10.07% |
| 4 | Financials | 8.17% |
| 5 | Communication Services | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
McKesson
MCK
$98.5B
| $70.4M | 0.11% |
458,357
-190,558
| -29% | -$29.7M |
|
227
Nasdaq
NDAQ
$51.5B
| $70.2M | 0.11% |
2,714,949
-312,417
| -10% | -$7.76M |
|
228
Automatic Data Processing
ADP
$100B
| $70.1M | 0.11% |
641,651
+639,196
| +26,036% | +$68.5M |
|
|
X
229
PUT
DELISTED
US Steel
X
| $70.1M | 0.11% |
2,731,900
+1,110,300
| +68% | +$27.2M |
|
|
LVLT
230
DELISTED
Level 3 Communications Inc
LVLT
| $69.7M | 0.11% |
1,307,910
+392,908
| +43% | +$21.9M |
|
|
MSCC
231
DELISTED
Microsemi Corp
MSCC
| $69.4M | 0.11% |
1,349,034
+550,609
| +69% | +$27.7M |
|
232
Charles River Laboratories
CRL
$10.9B
| $69.3M | 0.11% |
641,674
+107,447
| +20% | +$11M |
|
233
Healthpeak Properties
DOC
$15.4B
| $69.2M | 0.11% |
2,487,082
+1,028,349
| +70% | +$30.9M |
|
234
Cognizant
CTSH
$21.5B
| $69M | 0.11% |
951,344
-578,220
| -38% | -$40.6M |
|
235
Costco
COST
$415B
| $68.2M | 0.1% |
414,990
+33,906
| +9% | +$5.33M |
|
236
US Bancorp
USB
$99.6B
| $68.1M | 0.1% |
1,271,487
+639,438
| +101% | +$33.5M |
|
237
Crown Holdings
CCK
$12.8B
| $68M | 0.1% |
1,139,466
-262,868
| -19% | -$15.6M |
|
|
FOLD
238
DELISTED
Amicus Therapeutics
FOLD
| $67.9M | 0.1% |
4,505,500
+435,205
| +11% | +$5.76M |
|
|
MON
239
CALL
DELISTED
Monsanto Co
MON
| $67.5M | 0.1% |
563,400
+88,500
| +19% | +$10.4M |
|
|
VSM
240
DELISTED
Versum Materials, Inc.
VSM
| $66.7M | 0.1% |
1,718,163
-109,655
| -6% | -$3.92M |
|
|
MON
241
DELISTED
Monsanto Co
MON
| $65.9M | 0.1% |
549,971
-407,931
| -43% | -$48M |
|
242
Baidu
BIDU
$35.8B
| $65.8M | 0.1% |
+265,471
| New | +$57.9M |
|
243
United Therapeutics
UTHR
$26.3B
| $65M | 0.1% |
555,077
+161,936
| +41% | +$20.7M |
|
244
Nike
NKE
$61.9B
| $64.8M | 0.1% |
1,249,427
+838,569
| +204% | +$47.1M |
|
245
Insulet
PODD
$11.3B
| $64.6M | 0.1% |
1,173,715
-32,240
| -3% | -$1.76M |
|
246
Fastenal
FAST
$54B
| $64.6M | 0.1% |
5,673,312
+527,240
| +10% | +$5.68M |
|
247
CALL
Johnson & Johnson
JNJ
$635B
| $63.6M | 0.1% |
489,300
+45,100
| +10% | +$5.98M |
|
248
Freeport-McMoran
FCX
$90B
| $63.6M | 0.1% |
4,526,447
+405,474
| +10% | +$5.7M |
|
249
Celanese
CE
$5.09B
| $63M | 0.1% |
603,818
-220,942
| -27% | -$21.7M |
|
250
CALL
Verizon
VZ
$194B
| $62.6M | 0.1% |
1,265,000
+239,400
| +23% | +$11.3M |
|
Similar funds
D.E. Shaw & Co's Q3 2017 Portfolio in Review
As of Q3 2017, D.E. Shaw & Co held 3,794 positions worth $65.1B, up 7.7% from $60.5B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
D.E. Shaw & Co's Q3 2017 filing shows 469 new, 1,367 increased, 1,237 reduced and 370 closed positions. Its largest new stake was Baker Hughes: 3,076,914 shares worth $113M. The largest sale was Gilead Sciences, an estimated $356M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- D.E. Shaw & Co's largest Q3 2017 buy was Baker Hughes: 3,076,914 shares worth $113M.
- D.E. Shaw & Co added most to Comcast in Q3 2017, an estimated $354M increase.
- D.E. Shaw & Co's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $356M.
- D.E. Shaw & Co fully exited Mobileye N.V. in Q3 2017, selling an estimated $72.4M.
- D.E. Shaw & Co's ten largest holdings make up 9.6% of its $65.1B portfolio in Q3 2017.
- D.E. Shaw & Co opened 469 new positions and closed 370 in Q3 2017.
- D.E. Shaw & Co's portfolio value rose 7.7% quarter-over-quarter to $65.1B.
Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.